BACKGROUND: Defining the nature of the contribution of stroke to cognitive impairment remains challenging. OBJECTIVE: To describe associations between stroke history, APOE genotype, and subtypes of mild cognitive impairment (MCI). METHODS: We randomly selected residents from Olmsted County, Minnesota, aged 70 to 89 years on October 1, 2004, and invited eligible subjects without documented dementia to participate. Participants (n = 2050) were evaluated through an informant interview, a neurological evaluation, and neuropsychological testing. Neuropsychological testing included 9 tests to assess memory, attention, executive function, visuospatial cognition, and language. Subjects were diagnosed by consensus as cognitively normal or as having MCI (either amnestic or nonamnestic) or dementia. A history of stroke was obtained from the subjects and confirmed in their medical records. We computed the odds ratios (ORs) for a clinical diagnosis of MCI or for scoring in the lowest quartile on each cognitive domain. RESULTS: There were 1640 cognitively normal subjects and 329 subjects with MCI: 241 with amnestic MCI and 88 with nonamnestic MCI. In fully adjusted models with only subjects without dementia, a history of stroke was associated with a higher OR of nonamnestic MCI (OR, 2.85; 95% confidence interval [CI], 1.61-5.04) than amnestic MCI (OR, 1.77; 95% CI, 1.14-2.74). A history of stroke was also associated with impaired function in each cognitive domain except memory. The association was strongest for attention and executive function (OR, 2.48; 95% CI, 1.73-3.53). APOE epsilon4 genotype was associated only with amnestic MCI and with impaired memory function. CONCLUSIONS: In this population-based sample of persons without dementia, a history of stroke was particularly associated with nonamnestic MCI and impairment in nonmemory cognition. The APOE epsilon4 genotype was associated with memory impairment and amnestic MCI.
BACKGROUND: Defining the nature of the contribution of stroke to cognitive impairment remains challenging. OBJECTIVE: To describe associations between stroke history, APOE genotype, and subtypes of mild cognitive impairment (MCI). METHODS: We randomly selected residents from Olmsted County, Minnesota, aged 70 to 89 years on October 1, 2004, and invited eligible subjects without documented dementia to participate. Participants (n = 2050) were evaluated through an informant interview, a neurological evaluation, and neuropsychological testing. Neuropsychological testing included 9 tests to assess memory, attention, executive function, visuospatial cognition, and language. Subjects were diagnosed by consensus as cognitively normal or as having MCI (either amnestic or nonamnestic) or dementia. A history of stroke was obtained from the subjects and confirmed in their medical records. We computed the odds ratios (ORs) for a clinical diagnosis of MCI or for scoring in the lowest quartile on each cognitive domain. RESULTS: There were 1640 cognitively normal subjects and 329 subjects with MCI: 241 with amnestic MCI and 88 with nonamnestic MCI. In fully adjusted models with only subjects without dementia, a history of stroke was associated with a higher OR of nonamnestic MCI (OR, 2.85; 95% confidence interval [CI], 1.61-5.04) than amnestic MCI (OR, 1.77; 95% CI, 1.14-2.74). A history of stroke was also associated with impaired function in each cognitive domain except memory. The association was strongest for attention and executive function (OR, 2.48; 95% CI, 1.73-3.53). APOE epsilon4 genotype was associated only with amnestic MCI and with impaired memory function. CONCLUSIONS: In this population-based sample of persons without dementia, a history of stroke was particularly associated with nonamnestic MCI and impairment in nonmemory cognition. The APOE epsilon4 genotype was associated with memory impairment and amnestic MCI.
Authors: Rosebud O Roberts; Yonas E Geda; David S Knopman; Teresa J H Christianson; V Shane Pankratz; Bradley F Boeve; Adrian Vella; Walter A Rocca; Ronald C Petersen Journal: Arch Neurol Date: 2008-08
Authors: R C Petersen; G E Smith; R J Ivnik; E G Tangalos; D J Schaid; S N Thibodeau; E Kokmen; S C Waring; L T Kurland Journal: JAMA Date: 1995-04-26 Impact factor: 56.272
Authors: M Tullberg; E Fletcher; C DeCarli; D Mungas; B R Reed; D J Harvey; M W Weiner; H C Chui; W J Jagust Journal: Neurology Date: 2004-07-27 Impact factor: 9.910
Authors: Stephen R Rapp; Claudine Legault; Victor W Henderson; Robert L Brunner; Kamal Masaki; Beverly Jones; John Absher; Leon Thal Journal: Alzheimer Dis Assoc Disord Date: 2010 Jul-Sep Impact factor: 2.703
Authors: Rosebud O Roberts; Yonas E Geda; David S Knopman; Ruth H Cha; Bradley F Boeve; Robert J Ivnik; Vernon Shane Pankratz; Eric G Tangalos; Ronald C Petersen Journal: Alzheimer Dis Assoc Disord Date: 2010 Jan-Mar Impact factor: 2.703
Authors: Rosebud O Roberts; Yonas E Geda; David S Knopman; Bradley F Boeve; Teresa J H Christianson; V Shane Pankratz; Iftikhar J Kullo; Eric G Tangalos; Robert J Ivnik; Ronald C Petersen Journal: Alzheimers Dement Date: 2009-09 Impact factor: 21.566
Authors: V Shane Pankratz; Rosebud O Roberts; Michelle M Mielke; David S Knopman; Clifford R Jack; Yonas E Geda; Walter A Rocca; Ronald C Petersen Journal: Neurology Date: 2015-03-18 Impact factor: 9.910
Authors: Ryan T Muir; Benjamin Lam; Kie Honjo; Robin D Harry; Alicia A McNeely; Fu-Qiang Gao; Joel Ramirez; Christopher J M Scott; Anoop Ganda; Jiali Zhao; X Joe Zhou; Simon J Graham; Novena Rangwala; Erin Gibson; Nancy J Lobaugh; Alex Kiss; Donald T Stuss; David L Nyenhuis; Byung-Chul Lee; Yeonwook Kang; Sandra E Black Journal: Stroke Date: 2015-09-17 Impact factor: 7.914